A PILOT TRIAL OF SEQUENTIAL CHEMOTHERAPY WITH ANTIMETABOLITE INDUCTION, HIGH-DOSE ALKYLATING AGENT CONSOLIDATION WITH PERIPHERAL BLOOD PROGENITOR CELL SUPPORT, AND INTENSIFICATION WITH PACLITAXEL AND DOXORUBICIN FOR PATIENTS WITH HIGH-RISK BREAST CANCER: